Table 1 Baseline characteristics
Characteristic | Aumolertinib + Apatinib (N = 53) | Aumolertinib (N = 51) | P |
|---|---|---|---|
Age | 0.59 | ||
Median (range), y | 60 (33–75) | 61 (37–75) | |
Sex, No. (%) | 0.24 | ||
Male | 21 (40) | 26 (51) | |
Female | 32 (60) | 25 (49) | |
Smoking history, No. (%) | 0.91 | ||
Yes | 12 (23) | 12 (24) | |
No | 41 (77) | 39 (76) | |
Histology, No. (%) | 0.62 | ||
Adenocarcinoma | 51 (96) | 48 (94) | |
Others | 2 (4) | 3 (6) | |
Stage, No. (%) | 0.34 | ||
IIIB ~ IIIC | 1 (2) | 4 (8) | |
IV | 52 (98) | 47 (92) | |
EGFR mutation, No. (%) | 0.53 | ||
Exon 19 deletion | 25 (47) | 25 (49) | |
L858R | 27 (51) | 23 (45) | |
Othersa | 1 (2) | 3 (6) | |
ECOG | 0.94 | ||
0 | 7 (13) | 7 (14) | |
1 | 46 (87) | 44 (86) | |
Number of metastasis organs, No. (%) | 0.91 | ||
≥2 | 14 (26) | 14 (27) | |
<2 | 39 (74) | 37 (73) | |
CNS metastases, No. (%) | 0.57 | ||
Yes | 12 (23) | 14 (27) | |
No | 41 (77) | 37 (73) |
